Torok S; Rezeli M; Kelemen O; Vegvari A; Watanabe K; Sugihara Y; Tisza A; Marton T; Kovacs I; Tovari J; Laszlo V; Helbich TH; Hegedűs, Balázs; Klikovits T; Hoda MA; Klepetko W; Paku S; Marko-Varga G; Dome B
(2017)
Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, ...